Last reviewed · How we verify
NCT06932653: SurgPASS
Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial
NA trial testing SurgPASS - intervention in Post-operative Complications in 300 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | University of Birmingham |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 1 June 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 January 2026 |
| Sites | 5 locations across Ghana, Nigeria, Benin, Rwanda, India |
Drugs / interventions tested
- SurgPASS - intervention
Conditions studied
- Post-operative Complications — all drugs for Post-operative Complications →
Sponsor
University of Birmingham
Who can join
18 and older, any sex, with Post-operative Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SurgPASS is a pilot randomised cluster trial utilising a pre-operative checklist with the aim of reducing deaths after surgery. If SurgPASS is successful, the intervention will be implemented in a separate full-scale cluster randomised trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06932653
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-operative Complications
Currently open trials in the same condition.
- NCT06533111 — Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool · NA · recruiting
Other University of Birmingham trials
Trials by the same sponsor.
- NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
- NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
- NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
- NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
- NCT06923722 — De-stressing the Brain: Can Eating Grapes During Periods of Mental Stress Protect Brain and Vascular Health in Young Adu · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06932653 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06932653.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing